Diamond Therapeutics Inc. received a US patent (US12590110B2) for amorphous psilocybin compositions and associated treatment methods. The patent covers synthetic, a-polymorphic psilocybin formulations and processes for manufacturing, with CPC classifications in organic chemistry (C07F) and pharmaceutical preparations (A61K). The filing date was July 5, 2024.

Patent grants establish intellectual property rights but do not impose compliance obligations on other parties. Competitors developing psilocybin-based therapeutics should review the claims to assess potential freedom-to-operate concerns. No immediate action is required for entities not involved in psilocybin pharmaceutical development.